Editor's note

This article was originally published on 27 March 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The BCG problem

Bacillus Calmette-Guérin (BCG), first licensed in the 1920s, remains the world's only licensed tuberculosis vaccine - and its limitations are well-documented. While BCG provides strong protection against severe childhood forms of TB, including miliary TB and tuberculous meningitis, its efficacy against pulmonary tuberculosis in adults - the epidemiologically dominant form of the disease - is inconsistent and unreliable. Estimates of efficacy in clinical trials range from 0% to 80% depending on geography, age and strain, a variance so large as to render any commercial modelling highly uncertain.

Annual TB Deaths
~1.7m

Estimated annual global tuberculosis deaths in 2007, reinforcing the urgent need for a more effective vaccine despite BCG's continued use

The pipeline in 2008

By World TB Day 2008, a number of novel TB vaccine candidates had entered or were approaching clinical evaluation, including modified vaccinia Ankara (MVA85A), Mtb72F/AS02, and AERAS-402. Most were designed as boosters to BCG rather than standalone replacements, reflecting a pragmatic recognition that BCG's childhood protection benefits made complete replacement impractical. The challenge for Phase III development was defining appropriate endpoints that regulators would accept as a basis for licensure in the absence of a readily measurable correlate of protection.

"The TB vaccine pipeline of 2008 is more populated than at any point since BCG's development - but the scientific and regulatory hurdles are commensurately greater, and the commercial case remains difficult to make for traditional pharma."